search 


  home about us creating value our technologies pipeline news & events

studies

  site map
   
  NAMDRC 2010
March 18-20, 2009
San Diego, California
  RDD 2010
April 25-29, 2010
Orlando, Florida
  PARI nebulizers are considered the gold standard for clinical trials, and recommended in commercial sales including:

Pulmicort® (AstraZeneca)
Xopenex® (Sepracor)

Perforomist (Dey)
Brovana (Sepracor)

PARI nebulizers are the gold standard in inhalation therapy.

 

The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug.
PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.


We are currently working with both the eFlow® Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol delivery platforms.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.
 

 

 

Cystic Fibrosis

PARI’s Altera Delivers Gilead’s Cayston, Approved by European Commission to Treat Cystic Fibrosis [more]

- - - - - - - - - - - - - - - -

Cystic Fibrosis

Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma’s eFlow Technology [more]

- - - - - - - - - - - - - - - -

Cystic Fibrosis

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans [more]

 
     home  |  about us  |  creating value  |  our technologies  |  pipeline  |  news & events  |  studies

     © 2006-2008 PARI GmbH. All Rights Reserved.


PARI - 100 Years - Specialists in effective inhalation